Top

Published in:

01-07-2013 | Epidemiology

CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial

Authors: V. O. Dezentjé, R. H. N. van Schaik, J. M. Vletter-Bogaartz, T. van der Straaten, J. A. M. Wessels, E. M.-K. Kranenbarg, E. M. Berns, C. Seynaeve, H. Putter, C. J. H. van de Velde, J. W. R. Nortier, H. Gelderblom, H.-J. Guchelaar

Published in: Breast Cancer Research and Treatment | Issue 2/2013

Abstract

The clinical importance of CYP2D6 genotype as predictor of tamoxifen efficacy is still unclear. Recent genotyping studies on CYP2D6 using DNA derived from tumor blocks have been criticized because loss of heterozygosity (LOH) in tumors may lead to false genotype assignment. Postmenopausal early breast cancer patients who were randomized to receive tamoxifen, followed by exemestane in a large randomized controlled trial were genotyped for five CYP2D6 alleles. CYP2D6 genotypes and phenotypes were related to disease-free survival during tamoxifen use (DFS-t) in 731 patients. By analyzing microsatellites flanking the CYP2D6 gene, patients whose genotyping results were potentially affected by LOH were excluded. In addition, exploratory analyses on 24 genetic variants of other metabolic enzymes and the estrogen receptor were performed. For the CYP2D6 analysis, only 2.3 % of the samples were excluded, because influence of LOH could not be ruled out. No association was found between the CYP2D6 genotype or predicted phenotype and DFS-t (poor vs. extensive metabolizers: unadjusted hazard ratio 1.33, 95 % CI 0.52–3.43; P = 0.55). DFS-t was associated with UGT2B15*2 (Vt/Vt + Wt/Vt vs. Wt/Wt: adjusted hazard ratio 0.47, 95 % CI 0.25–0.89; P = 0.019) and the estrogen receptor-1 polymorphism ESR1 PvuII (gene–dose effect: adjusted hazard ratio 1.63, 95 % CI 1.04–2.54; P = 0.033). In postmenopausal early breast cancer patients treated with adjuvant tamoxifen followed by exemestane neither CYP2D6 genotype nor phenotype did affect DFS-t. This is in accordance with two recent studies in the BIG1-98 and ATAC trials. Our study is the first CYP2D6 association study using DNA from paraffin-embedded tumor tissue in which potentially false interpretation of genotyping results because of LOH was excluded. Polymorphisms in the estrogen receptor-1 and UGT2B15 may be associated with tamoxifen efficacy, but these findings need replication.

Available only for authorised users

Desta Z, Ward BA, Soukhova NV, Flockhart DA (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310:1062–1075PubMedCrossRef

Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P et al (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758–1764PubMedCrossRef

Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH et al (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30–39PubMedCrossRef

Lim YC, Desta Z, Flockhart DA, Skaar TC (2005) Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 55:471–478PubMedCrossRef

Lim YC, Li L, Desta Z, Zhao Q, Rae JM, Flockhart DA et al (2006) Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther 318:503–512PubMedCrossRef

Wu X, Hawse JR, Subramaniam M, Goetz MP, Ingle JN, Spelsberg TC (2009) The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res 69:1722–1727PubMedCrossRef

Murdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W et al (2011) Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 89:708–717. doi:10.1038/clpt.2011.27 PubMedCrossRef

Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW et al (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312–9318PubMedCrossRef

Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S et al (2009) Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302:1429–1436PubMedCrossRef

10.

Dezentje VO, Guchelaar HJ, Nortier JW, van de Velde CJ, Gelderblom H (2009) Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. Clin Cancer Res 15:15–21PubMedCrossRef

11.

Lash TL, Lien EA, Sorensen HT, Hamilton-Dutoit S (2009) Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol 10:825–833PubMedCrossRef

12.

Dezentje VO, van Blijderveen NJ, Gelderblom H, Putter H, van Herk-Sukel MP, Casparie MK et al (2010) Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol 28:2423–2429PubMedCrossRef

13.

Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC et al (2010) Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 340:c693PubMedCrossRef

14.

Abraham JE, Maranian MJ, Driver KE, Platte R, Kalmyrzaev B, Baynes C et al (2010) CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res 12:R64PubMedCrossRef

15.

Goetz M, Berry D, Klein T, International Tamoxifen Pharmacogenomics Consortium (2009) Adjuvant tamoxifen treatment outcome according to cytochrome P450 2D6 (CYP2D6) phenotype in early stage breast cancer: findings from the International Tamoxifen Pharmacogenomics Consortium. Cancer Res 69:33CrossRef

16.

Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R et al (2012) CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1–98 trial. J Natl Cancer Inst 104:441–451. doi:10.1093/jnci/djs125 PubMedCrossRef

17.

Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP et al (2012) CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 104:452–460. doi:10.1093/jnci/djs126 PubMedCrossRef

18.

Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW et al (2011) Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 89:718–725. doi:10.1038/clpt.2011.32 PubMedCrossRef

19.

Gjerde J, Hauglid M, Breilid H, Lundgren S, Varhaug JE, Kisanga ER et al (2008) Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol 19:56–61. doi:10.1093/annonc/mdm434 PubMedCrossRef

20.

Nishiyama T, Ogura K, Nakano H, Ohnuma T, Kaku T, Hiratsuka A et al (2002) Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases. Biochem Pharmacol 63:1817–1830PubMedCrossRef

21.

Sun D, Sharma AK, Dellinger RW, Blevins-Primeau AS, Balliet R, Chen G et al (2007) Glucuronidation of active tamoxifen metabolites by the human UDP-glucuronosyltransferases (UGTs). Drug Metab Dispos 35:2006–2014PubMedCrossRef

22.

Nakamura Y, Ratain MJ, Cox NJ, McLeod HL, Kroetz DL, Flockhart DA (2012) Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1–98 trial. J Natl Cancer Inst 104:1264–1268. doi:10.1093/jnci/djs304 PubMedCrossRef

23.

Pharoah PD, Abraham J, Caldas C (2012) Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1–98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 104:1263–1264. doi:10.1093/jnci/djs312 PubMedCrossRef

24.

Stanton V Jr (2012) Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1–98 trial. J Natl Cancer Inst 104:1265–1266. doi:10.1093/jnci/djs305 PubMedCrossRef

25.

Wheeler HE, Maitland ML, Dolan ME, Cox NJ, Ratain MJ (2012) Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet 14:23–34. doi:10.1038/nrg3352 PubMedCrossRef

26.

Castells A, Gusella JF, Ramesh V, Rustgi AK (2000) A region of deletion on chromosome 22q13 is common to human breast and colorectal cancers. Cancer Res 60:2836–2839PubMed

27.

van de Velde CJ, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM et al (2011) Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 377:321–331PubMedCrossRef

28.

Baak-Pablo R, Dezentje V, Guchelaar HJ, van der Straaten T (2010) Genotyping of DNA samples isolated from formalin-fixed paraffin-embedded tissues using preamplification. J Mol Diagn 12:746–749PubMedCrossRef

29.

Ahern TP, Christensen M, Cronin-Fenton DP, Lunetta KL, Rosenberg CL, Sorensen HT et al (2010) Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue. Clin Epidemiol 2:241–246. doi:10.2147/CLEP.S13811 PubMed

30.

Rae JM, Sikora MJ, Henry NL, Li L, Kim S, Oesterreich S et al (2009) Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J 9:258–264PubMedCrossRef

31.

Thompson AM, Johnson A, Quinlan P, Hillman G, Fontecha M, Bray SE et al (2010) Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat 125:279–287PubMedCrossRef

32.

Kiyotani K, Mushiroda T, Hosono N, Tsunoda T, Kubo M, Aki F et al (2010) Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response. Pharmacogenet Genomics 20:565–568PubMedCrossRef

33.

Court MH, Hao Q, Krishnaswamy S, Bekaii-Saab T, Al-Rohaimi A, von Moltke LL et al (2004) UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver. J Pharmacol Exp Ther 310:656–665PubMedCrossRef

34.

Ahern TP, Christensen M, Cronin-Fenton DP, Lunetta KL, Soiland H, Gjerde J et al (2011) Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors. Cancer Epidemiol Biomarkers Prev 20:1937–1943PubMedCrossRef

35.

Jin Y, Hayes DF, Li L, Robarge JD, Skaar TC, Philips S et al (2008) Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. J Clin Oncol 26:5849–5854PubMedCrossRef

36.

Onitilo AA, McCarty CA, Wilke RA, Glurich I, Engel JM, Flockhart DA et al (2009) Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy. Breast Cancer Res Treat 115:643–650PubMedCrossRef

37.

Hayes DF, Skaar TC, Rae JM, Henry NL, Nguyen AT, Stearns V et al (2010) Estrogen receptor genotypes, menopausal status, and the effects of tamoxifen on lipid levels: revised and updated results. Clin Pharmacol Ther 88:626–629. doi:10.1038/clpt.2010.143 PubMedCrossRef

38.

van Duijnhoven FJ, Peeters PH, Warren RM, Bingham SA, Uitterlinden AG, van Noord PA et al (2006) Influence of estrogen receptor alpha and progesterone receptor polymorphisms on the effects of hormone therapy on mammographic density. Cancer Epidemiol Biomarkers Prev 15:462–467PubMedCrossRef

39.

Cuzick J, Warwick J, Pinney E, Warren RM, Duffy SW (2004) Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 96:621–628PubMedCrossRef

40.

Grabinski JL, Chisholm G, Smith LS, Drengler RL, Kalter S, Rodriguez G et al. (2008) ER alpha genotypes and breast cancer recurrence. J Clin Oncol 26(15S):501

Title: CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial
Authors: V. O. Dezentjé
R. H. N. van Schaik
J. M. Vletter-Bogaartz
T. van der Straaten
J. A. M. Wessels
E. M.-K. Kranenbarg
E. M. Berns
C. Seynaeve
H. Putter
C. J. H. van de Velde
J. W. R. Nortier
H. Gelderblom
H.-J. Guchelaar
Publication date: 01-07-2013
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2013
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-013-2619-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2013

A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer

Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study

Margin status and the risk of local recurrence in patients with early-stage breast cancer treated with breast-conserving therapy

Dynamic changes in high and low mammographic density human breast tissues maintained in murine tissue engineering chambers during various murine peripartum states and over time

Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials

The associations between a polygenic score, reproductive and menstrual risk factors and breast cancer risk

Keynote webinar | Spotlight on antibody–drug conjugates in cancer